RxDoctor Payments Data

William Jackson, MD

Cardiovascular Disease · Myrtle Beach, SCNPI 1760471130

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $16,450 of the $25,418 with a category attached, or 64.7%. Johnson & Johnson accounts for 70.2% of it on its own, with 42 other manufacturers making up the rest. Reporting peaked in 2019 at $17,846 and has fallen 94.2% since, to $1,029 in 2025. Among cardiovascular disease clinicians in SC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$25,418in general payments, 2019–2025

Across 501 payments — averaging $50.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$18K
  • Biotronik Inc.$1K
  • Novartis$861
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$467
  • Pfizer$426
  • Amgen$422
  • plus $4K from 37 others

What the payments were for

  • Consulting fees$3001%
  • Speaking & faculty fees$16,45065%
  • Travel & lodging$2431%
  • Food & beverage$8,32333%
  • Education$1020%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,418 in reported general payments places this provider in the 90th percentile of 257 cardiovascular disease providers in South Carolina.

See all cardiovascular disease providers in South Carolina

Medicare billing

Part B allowed, 2024
$640,840
Medicare patients
4,617
Services billed
11,569

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban756$897,910
XareltoRivaroxaban334$416,916
EntrestoSacubitril/Valsartan90$101,166
Repatha SureclickEvolocumab30$38,040
MultaqDronedarone Hcl22$31,625
FarxigaDapagliflozin Propanediol11$16,416
Dofetilide26$12,795
Metoprolol Succinate767$12,391
Nebivolol Hcl144$9,819
Valsartan213$8,326
Rosuvastatin Calcium419$7,309
Atorvastatin Calcium614$6,894
Losartan Potassium498$6,272
Isosorbide Mononitrate ErIsosorbide Mononitrate286$6,127
Flecainide Acetate150$5,865

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$426$897,910756 claims
Johnson & JohnsonXarelto$17,846$416,916334 claims
NovartisEntresto$861$101,16690 claims
Sanofi-aventis U.S. LLCMultaq$229$31,62522 claims
AstraZenecaFarxiga$90$16,41611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 257 cardiovascular disease providers in South Carolina.

Other cardiovascular disease in Myrtle Beach

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →